drugset / Trial / NCT07810062
A Phase II Trial to Assess Extended Safety and Tolerability of Subcutaneous CAP256V2LS and VRC07-523LS in HIV- Negative Women
Phase 2
Completed
990 enrolled
Centre for Infectious Disease Research in Zambia
Amsterdam Institute for Global Health and Development · collabCentre for the AIDS Programme of Research in South Africa · collabEuropean and Developing Countries Clinical Trials Partnership (EDCTP) · collabMedical Research Council, South Africa · collabNational Institute of Communicable Diseases - NICD · collabUniversity of Cape Town · collab
RandomizedSingle-groupSingle-blindPrevention
Summary
A double blinded, Randomized, Placebo- controlled phase II trial to assess extended safety and tolerability of subcutaneous CAP256V2LS and VRC07-523LS in HIV- negative women
Timeline
- Start
- 2023-08-28
- Primary completion
- 2024-06-30
- Completion
- 2025-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CAP256V2LS | Monoclonal antibody | — | Subcutaneous |
| Subject | VRC07-523LS | Monoclonal antibody | — | Subcutaneous |
Indications
No indication recorded.